Annovis Bio IncNYSE:ANVS
- LAST PRICE5.5600
- TODAY'S CHANGE (%)-0.5300 (-8.7028%)
- Bid / Lots5.6000/ 1
- Ask / Lots5.9500/ 5
- Open / Previous Close5.9100 / 6.0900
- Day Range
- 52 Week Range
- Volume208,019
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ANVS |
|---|---|---|
| 09:32 ET | 20856 | 5.7 |
| 09:34 ET | 1100 | 5.875 |
| 09:36 ET | 3900 | 5.905 |
| 09:39 ET | 100 | 5.9145 |
| 09:41 ET | 300 | 5.95 |
| 09:43 ET | 2260 | 5.91 |
| 09:48 ET | 100 | 5.88 |
| 09:50 ET | 100 | 5.82 |
| 09:52 ET | 880 | 5.82 |
| 09:54 ET | 2280 | 5.835 |
| 09:59 ET | 631 | 5.835 |
| 10:01 ET | 130 | 5.82 |
| 10:03 ET | 1100 | 5.8101 |
| 10:06 ET | 4296 | 5.905 |
| 10:08 ET | 605 | 5.9 |
| 10:14 ET | 300 | 5.83 |
| 10:15 ET | 457 | 5.8996 |
| 10:17 ET | 1985 | 5.8715 |
| 10:19 ET | 710 | 5.89 |
| 10:28 ET | 2337 | 5.95 |
| 10:30 ET | 3300 | 5.92 |
| 10:42 ET | 5000 | 5.9001 |
| 10:46 ET | 1315 | 5.925 |
| 10:50 ET | 100 | 5.95 |
| 10:53 ET | 300 | 5.95 |
| 11:08 ET | 1700 | 5.9 |
| 11:22 ET | 332 | 5.885 |
| 11:24 ET | 100 | 5.885 |
| 11:38 ET | 1450 | 5.865 |
| 11:42 ET | 386 | 5.85 |
| 11:51 ET | 600 | 5.82 |
| 12:00 ET | 111 | 5.84 |
| 12:02 ET | 112 | 5.864 |
| 12:05 ET | 100 | 5.855 |
| 12:07 ET | 100 | 5.865 |
| 12:09 ET | 400 | 5.865 |
| 12:12 ET | 710 | 5.85 |
| 12:14 ET | 100 | 5.83 |
| 12:16 ET | 200 | 5.85 |
| 12:23 ET | 2492 | 5.8495 |
| 12:25 ET | 100 | 5.86 |
| 12:27 ET | 100 | 5.855 |
| 12:36 ET | 200 | 5.82 |
| 12:43 ET | 13452 | 5.805 |
| 12:50 ET | 1500 | 5.8 |
| 12:52 ET | 1163 | 5.8 |
| 12:54 ET | 7898 | 5.81 |
| 12:56 ET | 511 | 5.77 |
| 01:03 ET | 200 | 5.8 |
| 01:12 ET | 154 | 5.8 |
| 01:15 ET | 5500 | 5.805 |
| 01:17 ET | 1050 | 5.8 |
| 01:19 ET | 1000 | 5.8149 |
| 01:21 ET | 200 | 5.83 |
| 01:24 ET | 2200 | 5.805 |
| 01:28 ET | 3800 | 5.8 |
| 01:33 ET | 100 | 5.8 |
| 01:39 ET | 400 | 5.8145 |
| 01:44 ET | 1195 | 5.8299 |
| 01:48 ET | 100 | 5.83 |
| 01:51 ET | 600 | 5.85 |
| 01:53 ET | 240 | 5.863 |
| 02:04 ET | 200 | 5.85 |
| 02:08 ET | 179 | 5.84 |
| 02:09 ET | 100 | 5.85 |
| 02:13 ET | 100 | 5.85 |
| 02:22 ET | 390 | 5.85 |
| 02:31 ET | 1449 | 5.8475 |
| 02:42 ET | 1900 | 5.81 |
| 02:45 ET | 500 | 5.81 |
| 02:56 ET | 3797 | 5.81 |
| 02:58 ET | 5000 | 5.81 |
| 03:00 ET | 685 | 5.8 |
| 03:02 ET | 300 | 5.785 |
| 03:03 ET | 1300 | 5.78 |
| 03:07 ET | 426 | 5.8 |
| 03:20 ET | 100 | 5.8 |
| 03:34 ET | 1800 | 5.755 |
| 03:36 ET | 411 | 5.73 |
| 03:39 ET | 7995 | 5.685 |
| 03:45 ET | 100 | 5.6999 |
| 03:48 ET | 100 | 5.66 |
| 03:50 ET | 100 | 5.65 |
| 03:52 ET | 700 | 5.64 |
| 03:54 ET | 1465 | 5.6 |
| 03:56 ET | 5516 | 5.5301 |
| 03:57 ET | 3725 | 5.6 |
| 03:59 ET | 7834 | 5.56 |
Today
Jun 18, 2024
Annovis Bio Highlights New Alzheimer's Data at the Alzheimer's Association International Conference(R) 2024, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow JonesAnnovis Bio Highlights New Alzheimer's Data at the Alzheimer's Association International Conference(R) 2024, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 12, 2024
DJ Annovis Bio Price Target Maintained With a $23.00/Share by HC Wainwright & Co., from 6:54AM ET on Wednesday Jun 12, 2024 by Dow Jones
6:54AM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Annovis Bio Inc | 68.0M | -1.1x | --- |
Anebulo Pharmaceuticals Inc | 68.5M | -7.7x | --- |
Benitec Biopharma Inc | 67.5M | -0.7x | --- |
Maia Biotechnology Inc | 69.4M | -2.0x | --- |
CEL-SCI Corp | 66.6M | -2.0x | --- |
Aileron Therapeutics Inc | 66.5M | -0.9x | --- |
Company Information
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
Contact Information
- Headquarters
- 101 LINDENWOOD DRIVE, SUITE 225MALVERN, PA, United States 19355
- Phone
- 484-875-3192
- Fax
- 610-727-4001
Executives
- Independent Chairman of the Board
- Michael Hoffman
- President, Chief Executive Officer, Founder, Interim Principal Financial Officer, Director
- Maria Maccecchini
- Independent Director
- Claudine Bruck
- Independent Director
- Reid Mccarthy
- Independent Director
- Mark White
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $68.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 11.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.75 |
EPS | $-5.04 |
Book Value | $-0.74 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
